Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the ...

Moderna opens new vaccine facility in boost for UK pharmaceutical industry - The plant in Oxfordshire can make up to 100 ...

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the ...

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. The company said a preliminary analysis from a phase four clinical ...

Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and ...

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to ...

The chief executive of Moderna has hailed the UK as “a country that still believes in vaccination” as the US pharmaceutical ...